Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Giant Biogene Holding Co (HKSE:02367) Total Current Assets Explanation
In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.
Giant Biogene Holding Co's Liquidation Value for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Giant Biogene Holding Co Total Current Assets Related Terms
Giant Biogene Holding Co Total Current Assets Historical Data
* Premium members only.
The historical data trend for Giant Biogene Holding Co's Total Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Giant Biogene Holding Co Total Current Assets Chart
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.
What does a Total Current Assets of HK$10,045 Mil mean?
Giant Biogene Holding Co (HKSE:02367) has a Total Current Assets of HK$10,045 Mil as of Dec. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Giant Biogene Holding Co and its competitors.
Is Giant Biogene Holding Co's Total Current Assets too high?
Giant Biogene Holding Co's current Total Current Assets is HK$10,045 Mil. Overall, Giant Biogene Holding Co has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Giant Biogene Holding Co's Total Current Assets compare to PG and CL?
Giant Biogene Holding Co's Total Current Assets of HK$10,045 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Consumer Packaged Goods company?
A good Total Current Assets depends on the Consumer Packaged Goods industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Giant Biogene Holding Co and its competitors. Giant Biogene Holding Co's current Total Current Assets is HK$10,045 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Giant Biogene Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Giant Biogene Holding Co (HKSE:02367) is currently considered Possible Value Trap. The stock's GF Value™ is HK$68.03, compared to a current price of HK$24.46 — trading 64% below its estimated fair value. The current Total Current Assets is HK$10,045 Mil. Giant Biogene Holding Co's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Giant Biogene Holding Co (HKSE:02367), the current Total Current Assets is HK$10,045 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Giant Biogene Holding Co (HKSE:02367) Overvalued in 2026?
Based on GuruFocus' analysis, Giant Biogene Holding Co stock appears to be undervalued.
The current stock price of HK$24.46 is trading 64% below its estimated GF Value™ of HK$68.03.
GuruFocus considers Giant Biogene Holding Co to be Possible Value Trap.
Key valuation signals for HKSE:02367:
Total Current Assets: HK$10,045 Mil
GF Value™: HK$68.03 vs. price of HK$24.46 (64% below fair value)
No single metric tells the full story. See the HKSE:02367 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Giant Biogene Holding Co Ltd designs, develops, and manufactures professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenoside technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop & manufacture multiple types of recombinant collagen & rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty & health properties such as skin repair, anti-aging, whitening, moisturizing, & immunity improvement, with a broad range of applications in the beauty & health sectors. The group is organised into a single business unit that mainly includes the research, development, manufacture, & sale of bioactive material-based beauty & health products.
85GF Score
Get the complete analysis for HKSE:02367
Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02367 has been successfully added to your 
